Court rules against Cipla in valganciclovir trademark case
This article was originally published in Scrip
Executive Summary
The Bombay High Court has restrained Cipla from using the Valcept trademark for its cut-price generic version of Roche's Valcyte (valganciclovir) used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.